pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Endocrinology & Metabolism · news · pharmadog
← back to Endocrinology & Metabolism
News · Endocrinology & Metabolism
432
stories
11h
Novo’s consumer push gains momentum with Wegovy pill, CagriSema on deck
endpoints
19h
Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
biospace
1d
5 acquisitions that forced Big Pharmas to co-parent
biospace
1d
AstraZeneca, Calidi, Tempest make significant workforce cuts
biospace
1d
Scientists uncover ‘very detailed map’ of an enzyme target for rare metabolic disease
fiercebiotech
2d
Novo’s CagriSema drives more than 20% weight loss at lower doses
biospace
2d
ObesityWeek 2026: Wave outlines case for body composition–based trial design
biospace
2d
Seawolf surfaces with $100M, $1.2B Sanofi pact for redosable DNA medicines
biospace
2d
Seawolf launches with $100M to make non-viral gene therapies
endpoints
2d
Big-name investors pour $100M into DNA therapeutics developer Seawolf
biopharma dive
5d
Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026
biospace
5d
Charles River pays $470M for 2 Frontage bioanalysis labs in Pennsylvania
fiercebiotech
6d
Deep dive: Cardiovascular calamities and catalysts
biospace
6d
Big Pharma-backed Seawolf surfaces with $100M to hand, $1.2B Sanofi DNA med pact
fiercebiotech
6d
Blackstone bets $1.5B on Pfizer’s obesity drug
biopharma dive
6d
Neurosterix nabs $105M, recruits Karuna veterans for schizophrenia push
biospace
7d
Addex spinout Neurosterix raises $105M series B to fund phase 2 schizophrenia trial
fiercebiotech
7d
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
biospace
8d
Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorder
biospace
9d
STAT+: FDA approves novel Bayer drug to reduce recurrence of stroke
stat
9d
STAT+: Heart association meeting’s readout is trending ‘neutral’
stat
9d
Merck’s MASH hopeful efinopegdutide wins in mid-stage study
fiercebiotech
10d
Survival after sudden cardiac arrest didn’t improve despite training bystanders, emergency responders
stat
11d
Lowering blood pressure after stroke or with diabetes poses challenges, in research and practice
stat
11d
STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy
stat
11d
STAT+: Despite Novo drug’s failure, cardiologists say they will still pursue anti-inflammatories
stat
11d
Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
fiercebiotech
12d
Agios axes 100-plus R&D roles while awaiting FDA decision
biospace
12d
This week in charts: 3 drug launches Wall Street is watching
biopharma dive
13d
Medicare will cut billions from 340B, expand site-neutral payments in 2027
biopharma dive
← prev
page 1 of 15
next →